Home > Publications Database > CSF NFL in a Longitudinally Assessed PD Cohort: Age Effects and Cognitive Trajectories > print

001     151064
005     20250415091827.0
024 7 _ |a 10.1002/mds.28056
|2 doi
024 7 _ |a 0885-3185
|2 ISSN
024 7 _ |a 1531-8257
|2 ISSN
024 7 _ |a altmetric:82644976
|2 altmetric
024 7 _ |a pmid:32445500
|2 pmid
037 _ _ |a DZNE-2020-01049
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Lerche, Stefanie
|0 P:(DE-2719)2812186
|b 0
|e First author
245 _ _ |a CSF NFL in a Longitudinally Assessed PD Cohort: Age Effects and Cognitive Trajectories
260 _ _ |a New York, NY
|c 2020
|b Wiley
264 _ 1 |3 online
|2 Crossref
|b Wiley
|c 2020-05-23
264 _ 1 |3 print
|2 Crossref
|b Wiley
|c 2020-07-01
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1744701464_3428
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a BackgroundNeurofilament light protein is an unspecific biofluid marker that reflects the extent of neuronal/axonal damage and thereby offers the chance monitor disease severity and progression. The objective of this study was to investigate cerebrospinal fluid (CSF) levels of neurofilament light protein in Parkinson’s disease (PD) patients with clinical trajectories of motor and cognitive function longitudinally.MethodsCSF neurofilament light protein levels were assessed in 371 PDsporadic, 126 genetic PD patients (91 PDGBA, 8 PDLRRK2, 21 PDPRKN/PINK1/DJ1_heterozygous, 6 PDPRKN/PINK1/DJ1_homozygous), and 71 healthy controls. Participants were followed up longitudinally for up to 8 years.ResultsAt baseline, mean CSF neurofilament light protein levels were highest in PD patients with cognitive impairment (Montreal Cognitive Assessment score ≤ 25; 1207 pg/mL) but also higher in PD patients with normal cognitive function (757 pg/mL) compared with healthy controls (593 pg/mL; P ≤ 0.001). In healthy controls and in PD patients older age was associated with higher CSF levels of neurofilament light protein (P ≤ 0.001). In PD patients, male gender, older age at onset, longer disease duration, higher Hoehn and Yahr stages, higher UPDRS‐III scores, and lower Montreal Cognitive Assessment scores were associated with higher CSF levels of neurofilament light protein (P < 0.01). In patients who developed cognitive impairment during study, CSF neurofilament light protein levels prior to conversion to cognitive impairment were not significantly different compared with CSF neurofilament light protein levels of patients who remained cognitively normal.ConclusionsIncreased CSF levels of neurofilament light protein are associated with cognitive decline and motor impairment in PD. However, this increase seems not a very early event and does not mark the conversion to cognitive impairment beforehand. Therefore, the predictive value needs to be discussed critically. © 2020 International Parkinson and Movement Disorder Society.
536 _ _ |a 345 - Population Studies and Genetics (POF3-345)
|0 G:(DE-HGF)POF3-345
|c POF3-345
|f POF III
|x 0
542 _ _ |i 2020-05-23
|2 Crossref
|u http://onlinelibrary.wiley.com/termsAndConditions#vor
542 _ _ |i 2020-05-23
|2 Crossref
|u http://doi.wiley.com/10.1002/tdm_license_1.1
588 _ _ |a Dataset connected to CrossRef
650 _ 2 |a Age Factors
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Biomarkers
|2 MeSH
650 _ 2 |a Cognition
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: etiology
|2 MeSH
650 _ 2 |a Disease Progression
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Neurofilament Proteins: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Parkinson Disease: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Parkinson Disease: complications
|2 MeSH
700 1 _ |a Wurster, Isabel
|0 P:(DE-2719)2812736
|b 1
700 1 _ |a Röben, Benjamin
|0 P:(DE-2719)2811830
|b 2
700 1 _ |a Zimmermann, Milan
|0 P:(DE-2719)9000951
|b 3
700 1 _ |a Machetanz, Gerrit
|0 P:(DE-2719)9000193
|b 4
700 1 _ |a Wiethoff, Sarah
|0 P:(DE-2719)2814026
|b 5
700 1 _ |a Dehnert, Monique
|b 6
700 1 _ |a Rietschel, Lea
|b 7
700 1 _ |a Riebenbauer, Benjamin
|0 P:(DE-2719)9000377
|b 8
700 1 _ |a Deuschle, Christian
|0 P:(DE-2719)2812432
|b 9
700 1 _ |a Stransky, Elke
|0 P:(DE-2719)9000441
|b 10
700 1 _ |a Liepelt-Scarfone, Inga
|0 P:(DE-2719)2109499
|b 11
700 1 _ |a Gasser, Thomas
|0 P:(DE-2719)2320009
|b 12
700 1 _ |a Brockmann, Kathrin
|0 P:(DE-2719)2811916
|b 13
|e Last author
773 1 8 |a 10.1002/mds.28056
|b : Wiley, 2020-05-23
|n 7
|p 1138-1144
|3 journal-article
|2 Crossref
|t Movement Disorders
|v 35
|y 2020
|x 0885-3185
773 _ _ |a 10.1002/mds.28056
|g Vol. 35, no. 7, p. 1138 - 1144
|0 PERI:(DE-600)2041249-6
|n 7
|p 1138-1144
|t Movement disorders
|v 35
|y 2020
|x 0885-3185
856 4 _ |u https://onlinelibrary.wiley.com/doi/10.1002/mds.28056
856 4 _ |u https://pub.dzne.de/record/151064/files/DZNE-2020-01049_Restricted.pdf
856 4 _ |u https://pub.dzne.de/record/151064/files/DZNE-2020-01049_Restricted.pdf?subformat=pdfa
|x pdfa
909 C O |p VDB
|o oai:pub.dzne.de:151064
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)2812186
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)2812736
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2811830
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)9000951
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)9000193
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)2814026
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)9000377
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)2812432
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)9000441
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 11
|6 P:(DE-2719)2109499
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 12
|6 P:(DE-2719)2320009
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 13
|6 P:(DE-2719)2811916
913 1 _ |a DE-HGF
|b Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-345
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Population Studies and Genetics
|x 0
914 1 _ |y 2020
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2020-02-26
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2020-02-26
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2022-11-11
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b MOVEMENT DISORD : 2021
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-11
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-11
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b MOVEMENT DISORD : 2021
|d 2022-11-11
920 1 _ |0 I:(DE-2719)6000018
|k Tübingen common
|l Tübingen common
|x 0
920 1 _ |0 I:(DE-2719)1240004
|k Biobanking Facility (Tübingen)
|l Biobanking Facility (Tübingen)
|x 1
920 1 _ |0 I:(DE-2719)1210000
|k AG Gasser
|l Parkinson Genetics
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)6000018
980 _ _ |a I:(DE-2719)1240004
980 _ _ |a I:(DE-2719)1210000
980 _ _ |a UNRESTRICTED
999 C 5 |9 -- missing cx lookup --
|a 10.1007/BF00293376
|2 Crossref
|o 10.1007/BF00293376
999 C 5 |9 -- missing cx lookup --
|a 10.1001/jamaneurol.2018.3746
|2 Crossref
|o 10.1001/jamaneurol.2018.3746
999 C 5 |9 -- missing cx lookup --
|a 10.1002/mds.10459
|2 Crossref
|o 10.1002/mds.10459
999 C 5 |9 -- missing cx lookup --
|a 10.1002/mds.22340
|2 Crossref
|o 10.1002/mds.22340
999 C 5 |9 -- missing cx lookup --
|a 10.1002/mds.20213
|2 Crossref
|o 10.1002/mds.20213
999 C 5 |9 -- missing cx lookup --
|a 10.1212/WNL.0b013e3181c34b47
|2 Crossref
|o 10.1212/WNL.0b013e3181c34b47
999 C 5 |9 -- missing cx lookup --
|a 10.1016/0022-3956(75)90026-6
|2 Crossref
|o 10.1016/0022-3956(75)90026-6
999 C 5 |9 -- missing cx lookup --
|a 10.1111/jgs.14779
|2 Crossref
|o 10.1111/jgs.14779
999 C 5 |9 -- missing cx lookup --
|a 10.1207/s15327752jpa6703_13
|2 Crossref
|o 10.1207/s15327752jpa6703_13
999 C 5 |9 -- missing cx lookup --
|a 10.1212/WNL.0000000000008088
|2 Crossref
|o 10.1212/WNL.0000000000008088
999 C 5 |9 -- missing cx lookup --
|a 10.1038/s41598-018-35766-w
|2 Crossref
|o 10.1038/s41598-018-35766-w
999 C 5 |9 -- missing cx lookup --
|a 10.1002/ana.24777
|2 Crossref
|o 10.1002/ana.24777
999 C 5 |9 -- missing cx lookup --
|a 10.1002/mds.27884
|2 Crossref
|o 10.1002/mds.27884
999 C 5 |9 -- missing cx lookup --
|a 10.1038/s41591-018-0304-3
|2 Crossref
|o 10.1038/s41591-018-0304-3
999 C 5 |9 -- missing cx lookup --
|a 10.1016/j.parkreldis.2019.04.020
|2 Crossref
|o 10.1016/j.parkreldis.2019.04.020

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21